Skip to main content
Pharmena S.A. logo

Pharmena S.A. — Investor Relations & Filings

Ticker · PHR ISIN · PLPHRMN00011 LEI · 259400RHT936BBKW0955 WAR Manufacturing
Open in API
Filings indexed 649 across all filing types
Latest filing 2018-07-06 Capital/Financing Update
Country PL Poland
Listing WAR PHR

About Pharmena S.A.

https://www.pharmena.eu/

Pharmena S.A. is a specialty healthcare company focused on the development and commercialization of innovative products based on its patented active ingredient, 1-MNA. This molecule is a naturally occurring metabolite of niacin (vitamin B3) that plays a crucial role in cellular metabolism. The company's technology leverages the ability of 1-MNA to optimize the levels of the coenzyme NAD+, which decline with age and are vital for cellular function and regeneration. The product portfolio includes specialized cosmeceuticals, such as the Dermena line for hair loss, and dietary supplements designed to address the effects of cellular aging.

Recent filings

Filing Released Lang Actions
Podwyższenie kapitału zakładowego i przeniesienia akcji PHARMENA S.A. na rynek regulowany - Content (PL)
Capital/Financing Update Classification · 98% confidence The document text, written in Polish, details the Management Board's resolution (dated July 6, 2018) to initiate actions for: 1) increasing share capital via a private subscription (issuing up to 2,638,516 new shares, Series E), 2) moving the company's shares from the NewConnect alternative trading system to the regulated market of the Warsaw Stock Exchange (GPW), and 3) seeking admission for the new shares and subscription rights to the regulated market. The purpose of the share issue is explicitly stated as raising financing for product development and market entry. The text concludes by stating that these actions require resolutions from the General Shareholders' Meeting (Walne Zgromadzenie Akcjonariuszy) and that a separate report will announce the convening of an Extraordinary General Meeting (Nadzwyczajne Walne Zgromadzenie Akcjonariuszy). This content directly relates to fundraising, capital structure changes (share issuance/capital increase), and moving listings, which strongly aligns with the 'Capital/Financing Update' definition (CAP). Although it mentions a future General Meeting, the primary focus is the capital raising plan itself, not the voting results (DVA) or the AGM presentation (AGM-R). It is a definitive announcement of a financing plan.
2018-07-06 Polish
PHARMENA_Wykaz akcjonariuszy posiad. pow. 5%głosów na ZWZ w dniu 20 06 2018 r.
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is titled 'Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na Zwyczajnym Walnym Zgromadzeniu Pharmena S.A. w dniu 20.06.2018 r.', which translates to 'List of shareholders holding at least 5% of the votes at the Ordinary General Meeting of Pharmena S.A. on 20.06.2018'. This content explicitly details the results of voting rights or the distribution of votes/shareholdings related to a General Meeting. This aligns directly with the definition for 'Declaration of Voting Results & Voting Rights Announcements' (DVA). It is not an AGM presentation (AGM-R), nor is it a general management change (MANG) or a standard earnings report (ER/IR).
2018-06-21 Polish
Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na ZWZ w dniu 20.06.2018 r. - Content (PL)
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document text is very short (383 characters) and explicitly states that the Management Board of PHARMENA S.A. is attaching a list of shareholders holding at least 5% of the votes from the Annual General Meeting (Zwyczajnym Walnym Zgromadzeniu) held on 20.06.2018. This content—a list of major shareholders' voting rights following a general meeting—is a specific disclosure related to voting results or shareholder structure following a meeting. While it relates to the AGM, the most precise category for official results from shareholder votes is 'Declaration of Voting Results & Voting Rights Announcements' (DVA). It is not the AGM presentation itself (AGM-R), nor is it a general regulatory filing (RNS), as DVA is more specific.
2018-06-21 Polish
Rozpoczęcie procesu przygotowania dokumentacji i autoryzacji 1-MNA na wybranych rynkach światowych. - Content (PL)
Regulatory Filings Classification · 92% confidence The document is a short announcement (1389 characters) from the Management Board (Zarząd) of PHARMENA S.A. It details the results of an analysis regarding the introduction of a dietary supplement containing 1-MNA into markets like China, Japan, India, and Australia. It explicitly states the intention to start preparing documentation for registration and authorization in these markets. This is not a full financial report (10-K, IR) or a standard earnings release (ER). It concerns strategic business development and potential future revenue impact, but it is primarily an announcement about future regulatory/market entry steps. Given its nature as a strategic business update that is not explicitly covered by other codes (like M&A, Financing, or Director's Dealing), and its brevity suggesting it's an announcement rather than a detailed report, it fits best under the general 'Regulatory Filings' (RNS) category as a significant business update, or potentially 'Capital/Financing Update' (CAP) if the authorization process is viewed as a major strategic investment, but RNS is the safer fallback for non-standard strategic news. Since it announces a strategic business move that will require significant regulatory steps, and it is not a formal report, RNS is the most appropriate general classification.
2018-06-13 Polish
Przyjęcie projektu rozporządzenia Komisji Europejskiej ws. autoryzacji 1-MNA jako nowego składnika żywności - Content (PL)
Regulatory Filings Classification · 95% confidence The document is a formal announcement (raport bieżący) from the Management Board (Zarząd) of PHARMENA S.A. regarding a significant regulatory approval for a new food ingredient (1-MNA) by the European Commission's Standing Committee (SCoPAFF). It details the positive assessment, the granting of five-year data protection, and the expected publication timeline in the Official Journal of the EU. This concerns a major development impacting the company's product launch and future revenue, which is a type of corporate event disclosure. Since it is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a specific shareholder vote result (DVA), it falls under general regulatory announcements. Given the nature of the announcement—reporting on a regulatory decision that enables future commercial activity—it is best classified as a general Regulatory Filing (RNS), as it is a mandatory disclosure of a material event that doesn't fit the more specific categories like M&A (TAR) or Capital Change (CAP). The document length is short (2708 chars), but it is the primary disclosure itself, not an announcement *about* a report, so RPA is less appropriate than RNS for this type of regulatory news.
2018-06-12 Polish
Wyznaczenie terminu oceny wniosku o autoryzację 1-MNA jako nowego składnika żywności poprzez Stały Komitet Komisji Europejskiej ds. Roślin, Zwierząt, Żywności i Pasz SCoPAFF. - Content (PL)
Regulatory Filings Classification · 95% confidence The document is a formal communication from the Management Board (Zarząd) of PHARMENA S.A. It references previous regulatory filings (raport bieżący nr 7/2018 and 8/2018) regarding the authorization process for a new food ingredient (1-MNA) by the European Commission's Standing Committee (SCoPAFF). The text details the upcoming evaluation date (June 11th) and explains the potential significant impact of obtaining market authorization on the company's future revenues. This type of communication, updating stakeholders on a specific regulatory or legal process that could materially affect the company's business or financial outlook, fits best under the general category of Regulatory Filings (RNS), as it is not a full financial report (10-K, IR), an earnings release (ER), or a specific management discussion (MDA). It is an update on a regulatory/legal matter.
2018-05-24 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.